The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia

doi 10.20944/preprints202004.0224.v1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Drug Repurposing for the Treatment of Acute Myeloid Leukemia

Frontiers in Medicine
Medicine
2017English

Phase 1 Study of the MDM2 Antagonist RO6839921 in Patients With Acute Myeloid Leukemia

Investigational New Drugs
OncologyPharmacology
2020English

Neurokinin-1 Receptor Antagonist Treatment Protects Mice Against Lung Injury in Polymicrobial Sepsis

Journal of Leukocyte Biology
AllergyImmunologyCell Biology
2007English

Molecular Emergence of Acute Myeloid Leukemia During Treatment for Acute Lymphoblastic Leukemia

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
2001English

AML1 (Acute Myeloid Leukemia 1)

Atlas of Genetics and Cytogenetics in Oncology and Haematology
Cancer ResearchOncologyGeneticsHematology
2010English

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2011English

Intrathecal Neurokinin-1 Receptor Antagonist Reduces Isoflurane MAC in Rats

Canadian Journal of Anaesthesia
MedicineAnesthesiologyPain Medicine
1997English

Advances in Treatment Formulations for Acute Myeloid Leukemia

Drug Discovery Today
Drug DiscoveryPharmacology
2018English

Repositioning of Bromocriptine for Treatment of Acute Myeloid Leukemia

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy